CPI Logo-Color.png
Constellation Pharmaceuticals Provides Updates of MANIFEST Study for CPI-0610 and EZH2 Franchise
June 12, 2020 02:30 ET | Constellation Pharmaceuticals , Inc.
Spleen response rates in first-line patients at 12 weeks and 24 weeks in line with previously reported data and differentiated from standard of careSpleen responses demonstrated in...
CPI Logo-Color.png
Constellation Pharmaceuticals to Participate in Investor Conference
May 29, 2020 09:00 ET | Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., May 29, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
CPI Logo-Color.png
Constellation Pharmaceuticals Announces First-Quarter 2020 Financial Results
May 06, 2020 07:00 ET | Constellation Pharmaceuticals , Inc.
EHA abstracts to publish on May 14 with an interim update across the MANIFEST trial cohortsConstellation to provide an additional interim update from MANIFEST at EHA in mid-June Company continues to...
CPI Logo-Color.png
Constellation Pharmaceuticals to Participate in Two Investor Conferences
May 05, 2020 14:06 ET | Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., May 05, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
CPI Logo-Color.png
Constellation Pharmaceuticals to Host Conference Call to Discuss First Quarter 2020 Results
April 28, 2020 09:00 ET | Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., April 28, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop...
CPI Logo-Color.png
Constellation Pharmaceuticals Announces Fourth-Quarter and Full-Year 2019 Financial Results
March 10, 2020 16:12 ET | Constellation Pharmaceuticals , Inc.
Clinical data presented at 2019 American Society of Hematology (ASH) annual meeting suggested that CPI-0610 could offer meaningful benefits beyond standard of care in myelofibrosis In addition to...
CPI Logo-Color.png
Constellation Pharmaceuticals to Host Conference Call to Discuss Fourth Quarter 2019 Results
March 06, 2020 13:00 ET | Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., March 06, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel...
CPI Logo-Color.png
Constellation Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
January 06, 2020 12:33 ET | Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
CPI Logo-Color.png
Constellation Pharmaceuticals to Participate in Upcoming Investor Conferences
November 13, 2019 09:00 ET | Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
CPI Logo-Color.png
Constellation Pharmaceuticals Announces Third-Quarter and Nine-Month 2019 Financial Results
November 06, 2019 09:00 ET | Constellation Pharmaceuticals , Inc.
First MANIFEST data showing signs of CPI-0610 clinical activity in JAK-inhibitor-naïve myelofibrosis patients Data showing signs of continuing activity in ruxolitinib-refractory or -intolerant...